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include these effects and this appears not to inﬂuence results in
general. More empirical work is needed, using generic instru-
ments, larger and more relevant samples, and perhaps using the
interview method of administration.
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OBJECTIVES: Expensive drugs for rare disorders (EDRDs;
“orphan drugs”) do not usually meet widely applied cost-
effectiveness benchmarks (“lambdas”). Adopting the standard
decision rules of the logic cost-effectiveness cannot be reconciled
with granting reimbursement status for many EDRDs and would
inevitably deprive patients with very rare disorders from any
chance to get access to effective treatment, given the high ﬁxed /
low variable cost structure of the pharmaceutical industry. On
the other hand, public policies have been established to provide
incentives to support development of orphan drugs. This (and
some further observations) suggests a serious mismatch between
the logic of cost-effectiveness and societal preferences. Decision-
makers have responded; for instance, the National Institute for
Health and Clinical Excellence (NICE) attempts to deﬁne a
special subcategory of “ultra-orphans”—while maintaining that
budgetary impact analysis is not part of its appraisal decisions
(but limited to implementation support). This policy, however,
does not appear to adequately address the underlying problem.
METHODS: First, “ultra-orphans” are not a distinct, well-
deﬁned category—they rather represent one extreme of a
continuous spectrum, and “orphan drugs” and some cancer
treatments pose the same fundamental problem. Second, size of a
patient population eligible for treatment is directly linked to
budgetary impact (and hence the opportunity for manufacturers
to recoup ﬁxed costs), whereas the logic of cost-effectiveness is
impaired by not taking into account the size of the numerator
and the denominator of the incremental cost-effectiveness ratio
(ICER), which has been described as “the silence of the lambda.”
Policy makers might address these issues by explicitly taking
budgetary impact into account when deciding on maximum
reimbursement prices or by price-volume agreements. RESULTS:
Both approaches, albeit perhaps pragmatic, cannot satisfy from a
theoretical economic perspective. CONCLUSIONS: Rigorous
normative analysis and empirical research are required to further
explore the mapping of individual health-related utilities into
societal preferences (willingness-to-pay).
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OBJECTIVES: To determine if and to what extent records
obtained from PBM pharmacy claims differ from source docu-
ments obtained directly from pharmacy providers. Also this
study sought to explore possible associations between patient,
pharmacy beneﬁt, and pharmacy provider characteristics and the
likelihood a patient would have missing prescription claims.
METHODS: This study used a cross sectional survey of 1,484
patients residing in a single state with a common pharmacy
beneﬁt. Patient proﬁles describing all prescriptions ﬁlled in a
pharmacy between January 1, 2002 through June 30, 2002 of
these patients were requested directly from their pharmacy pro-
viders. Logistic regression was used to explore the factors asso-
ciated with a person receiving a prescription that did not appear
on the PBM claims. RESULTS: Of the 1484 eligible recipients
sampled, proﬁles were obtained for 323 (22%) persons and there
were analyzable proﬁles for 315 (21%) persons. Of those 2,977
prescriptions ﬁlled for the 315 persons, 207 (7.0%) were missing
from the claims ﬁles indicating that 93% were captured. Pre-
scription drugs such as iron products, digoxins, diuretics, sulfo-
nylureas, and antigout were more likely to be missing from the
PBM claims. Only prescription volume consistently inﬂuenced
the likelihood a patient would have a missing prescription from
the PBM claims (OR = 1.08; 95% CI: 1.05–1.12). CONCLU-
SIONS: Claims obtained from pharmacy beneﬁt companies
capture approximately 93% of prescription records when veri-
ﬁed with records obtained from pharmacy providers. The rate of
missing records from PBM claims does not appear to be mean-
ingfully inﬂuenced by most ﬁnance based pharmacy beneﬁt
design features, however, certain drugs available over the counter
and less expensive drugs may have less complete claims records
compared to other classes of drugs. Higher prescription utilizers
are more likely to have prescription records ﬁlled that are not
captured by PBMs.
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OBJECTIVE: The core of a cost effectiveness model should be
guided by the underlying disease process, natural history and
how particular interventions impact on disease. The development
of conceptual models within PRO research is based on the same
rationale. The objective of this study was to explore the overlap
between cost effectiveness modelling and conceptual models for
PROs, using AD as an example. METHODS: A conceptual
model of AD was reviewed alongside a cost effectiveness model
by a team of PRO researchers and health economists. Areas of
commonality and divergence were documented and discussed.
RESULTS: Points of overlap were identiﬁed which included the
impact of AD on day to day functioning of the patient and
associated caregiver burden. This will inﬂuence the ability of the
caregiver to work and impact on other resource utilisation. This
may, also have an impact on the time to institutionalisation,
which is a major ﬁnancial burden in AD. One major area of
divergence is the emphasis in economic models on the use of
generic quality of life data; whereas conceptual models are
commonly developed to measure disease speciﬁc PRO burden.
CONCLUSIONS: The commonalities between PRO conceptual
models and health economic models indicates the potential for
developing PRO and HE models simultaneously. This is likely to
increase the validity of each of the models as well as having a
positive impact on related research e.g. through the development
of health state utilities. As a next step we are prospectively
developing a conceptual model of disease which is speciﬁcally
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designed to support both the collection of PRO data and the
development of an economic model.
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OBJECTIVES: Behavioral health interventions traditionally use
a simple dichotomous outcome criterion: ‘success’ or ‘failure’.
In reality, though, behavior change is a complex process in
which several steps towards success are taken. There has been
little consideration, however, about whether future behavior
change should be incorporated in cost-effectiveness analyses
(CEAs). The aim of the present review is to identify and evalu-
ate the usage of cognitive, intermediate outcomes in CEAs of
behavioral interventions. METHODS: Electronic data sources
(PsycInfo, WebofScience, Medline, ScienceDirect and Scopus)
were searched for CEAs published before February 2008.
RESULTS: Most CEAs and CUAs reporting cognitive, interme-
diate outcomes of behavior change fail to incorporate partial
behavior changes. Only nine studies were eligible for inclusion
in this review. Smith et al 2007 [1] conducted the only study in
which partial behavior change was incorporated in the ﬁnal
outcome by modeling cognitive, intermediate outcomes: the
stages of change, derived from the Transtheoretical model
(TTM). The TTM is a stage-oriented model that describes the
process by which a change in behavior takes place. It describes
the readiness to change and the processes employed by indi-
viduals to achieve behavioral change. With inclusion of future
behavior change, Smith et al showed that the incremental cost-
effectiveness ratio declined compared to the standard analysis.
CONCLUSIONS: The results suggest that CEAs of behavioral
interventions can be further optimized by the measurement of
intermediate outcomes and use these to determine partial
behavior change at the end of an intervention period as well. In
other words, when partial behavior change and relapse rates
are incorporated in CEAs of behavioral treatments, a more
realistic and transparent ﬁnal outcome can be calculated. [1]
Smith, MY, Cromwell, J, DePue, J, et al. Determining the cost-
effectiveness of a computer-based smoking cessation interven-
tion in primary care. Managed Care 2007;16:48–55.
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OBJECTIVES: To develop a quantitative model that can deter-
mine the effect of segmentation and positioning on revenue
generation based on different variables, health economic consid-
erations and pricing scenarios, creating a tool which is easy to use
for the ﬁrst evaluation of options. METHODS: Literature review
and interviews with industry experts were conducted followed by
the development of qualitative framework, logic and the subse-
quently a quantitative model. The model was tested and vali-
dated using real life examples. RESULTS: A qualitative model
was developed which presents an iterative strategy to align stake-
holders’ interest with different scenarios of segmentation. From a
given asset base of active ingredients, the pharmaceutical
company deﬁnes therapeutic areas for a component and deter-
mines segments within them, evaluating both attractiveness and
speciﬁc propositions for patients, payers and prescribers in com-
prehensive scenarios. For the payer’s perspective in particular,
health economic beneﬁts of the proposed segmentation approach
must be contemplated. Following this analysis, objectives and
strategies for the chosen segments are developed and a holistic
value proposition can be delivered to the market. Ideally, the
process should be initiated early during development in order to
design clinical trials according to the segmentation strategy. The
process should also be monitored throughout the marketing and
sales process in order to make improvements, and to react to
changes in health care policies or the competitive landscape.
Following the qualitative analysis, a quantitative model was
developed in Excel that captures the effect of multiple variables
such as age, gender, disease severity, co-morbidities, insurance
type and multiple price points on revenue generation, positioning
and pricing of pharmaceuticals. The model was tested and vali-
dated using the example of bipolar disorder (BPD) in women
with childbearing potential. A new product with lower teratoge-
nic risks was evaluated along different segmentation scenarios in
order to determine improved overall cost-effectiveness when
compared to conventional treatments. CONCLUSIONS: Seg-
mentation is an important tool that could lead to better revenue
generation from the company’s perspective and is accepted posi-
tively by payers due to optimized budget impact with better
health outcomes.
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BACKGROUND: In model-based health economic evaluations,
to achieve a given level of precision surrounding modelled
outputs there is a trade-off between treatment effect estimates
and the computational time associated with the programming
format used to ‘code’ the model. OBJECTIVES: To explore the
relationship between modelled effect size, statistical precision
and the computational time associated with two commonly used
programming frameworks. METHODS: A published and vali-
dated cost-utility discrete event simulation (DES) diabetes model
(Cardiff model) was programmed in MS Excel with Visual Basic
(VB), and more recently reprogrammed in C as with other
models in this area, to illustrate the efﬁciency gains in terms of
computational speed achieved under different programming
frameworks. A treatment effect of 0.4% HbA1c improvement
was applied to a mean cohort proﬁle of 10,000 patients; preci-
sion in the predicted number of clinical events was used to assess
relative efﬁciency of VB and C. RESULTS: In the C programmed
model in order to show a signiﬁcant difference at the 95% level
in the predicted number of events in the control and treatment
arms required 50 iterations of the model using mean values. This
equated to a model run time of 1 minute. The equivalent number
of iterations in VB took 133 minutes to demonstrate a signiﬁcant
difference in the predicted number of events. Typically, one-way
sensitivity analysis using this model to explore 40 scenarios
would equate to a run time of 40 minutes in C and 5,320 minutes
(88.7 hours) in VB. CONCLUSIONS: Programming format can
impact the computational time associated with running the
model with subsequent practical implications for the usability of
the model. We conclude that with reasonably complex models,
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